PRECIGEN Investors

Events & Presentations

Events & Presentations

Upcoming Events

Dec 11, 2021 at 5:30 PM - 7:50 PM EST
An abstract highlighting PRGN-3007 preclinical data (Abstract# 1694) titled, “Preclinical evaluation of PRGN-3007, a non-viral, multigenic, autologous ROR1 UltraCAR-T® cell therapy with novel mechanism of intrinsic PD-1 blockade for treatment of hematological and solid cancers,” will be presented as a poster presentation.
Read More
Dec 13, 2021 at 5:00 PM EST
An abstract for the PRGN-3006 Phase 1 trial (Abstract# 825) titled, "Phase 1/1b Safety Study of PRGN-3006 UltraCAR-T in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes," was selected for oral presentation and will be presented by David Sallman, MD, Assistant Member in the Department of Malignant Hematology at the H. Lee Moffitt Cancer Center & Research Institute and a lead investigator for the PRGN-3006 clinical trial.
Read More

Past Events

Nov 12, 2021

A trial-in-progress update on the PRGN-2009 study titled, “Initial safety results and immune responses induced by a novel human papillomavirus (HPV)-specific gorilla adenovirus immunotherapy vaccine, PRGN-2009, in patients with advanced HPV-associated cancers,” was presented as a poster presentation (#483) by Charalampos S. Floudas, MD, DMSc, MS, Assistant Research Physician, Genitourinary Malignancies Branch at the Center for Cancer Research at the National Cancer Institute (NCI).

Read More
Oct 01, 2021 at 12:00 PM CEST
The abstract entitled, "AG019 ActoBiotics as monotherapy or in association with teplizumab in recent-onset type 1 diabetes was safe and demonstrated encouraging metabolic and immunological effects" was presented by Chantal Mathieu, MD, PhD, Professor of Medicine at the Katholieke Universiteit Leuven, Belgium.
Read More
Jun 10, 2021 at 5:05 PM - 5:20 PM EDT

Oral presentation of the AG019 abstract "Lactococcus lactis producing Proinsulin and IL-10 therapy increases Antigen Specific Regulatory T-cells in Monotherapy and in Combination with an anti-CD3 Monoclonal Antibody (Teplizumab) in newly diagnosed T1D patients." The abstract was presented by Kevan Herold, MD, CNH Long Professor of Immunobiology and of Medicine (Endocrinology) at the Yale School of Medicine. 

Read More
Jun 04, 2021 at 9:00 AM EDT
Trial-in-progress poster presentation of the PRGN-2009 abstract "First-in-human Phase I/II trial of PRGN-2009 vaccine as monotherapy or with bintrafusp alfa in patients with recurrent/metastatic (R/M) human papillomavirus (HPV)-associated cancers (HPVC) and as neoadjuvant/induction therapy in locoregionally advanced (LA) HPV oropharyngeal (OP) and sinonasal (SN) squamous cell cancer (SCC)." The poster presentation will be presented by Charalampos S. Floudas, MD, DMSc, MS, Assistant Research Physician, Genitourinary Malignancies Branch at the Center for Cancer Research at the National Cancer Institute (NCI). Presented in Poster Sessions: Head and Neck Cancer.
Read More